KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Shares OutstandingShares Repurchased
Ratios

Halozyme Therapeutics (HALO) Accumulated Depreciation & Amortization (2016 - 2025)

Historic Accumulated Depreciation & Amortization for Halozyme Therapeutics (HALO) over the last 16 years, with Q4 2025 value amounting to $11.4 million.

  • Halozyme Therapeutics' Accumulated Depreciation & Amortization rose 1067.96% to $11.4 million in Q4 2025 from the same period last year, while for Dec 2025 it was $11.4 million, marking a year-over-year increase of 1067.96%. This contributed to the annual value of $11.4 million for FY2025, which is 1067.96% up from last year.
  • Halozyme Therapeutics' Accumulated Depreciation & Amortization amounted to $11.4 million in Q4 2025, which was up 1067.96% from $2.7 million recorded in Q3 2025.
  • Halozyme Therapeutics' 5-year Accumulated Depreciation & Amortization high stood at $11.4 million for Q4 2025, and its period low was $700000.0 during Q3 2021.
  • Over the past 5 years, Halozyme Therapeutics' median Accumulated Depreciation & Amortization value was $2.7 million (recorded in 2023), while the average stood at $3.6 million.
  • Its Accumulated Depreciation & Amortization has fluctuated over the past 5 years, first plummeted by 1800.0% in 2021, then skyrocketed by 22775.0% in 2023.
  • Over the past 5 years, Halozyme Therapeutics' Accumulated Depreciation & Amortization (Quarter) stood at $3.0 million in 2021, then soared by 116.67% to $6.5 million in 2022, then surged by 70.77% to $11.1 million in 2023, then dropped by 7.21% to $10.3 million in 2024, then grew by 10.68% to $11.4 million in 2025.
  • Its last three reported values are $11.4 million in Q4 2025, $2.7 million for Q3 2025, and $2.7 million during Q2 2025.